{'fraction_non_alphanumeric': 0.016748768472906402, 'fraction_numerical': 0.0, 'mean_word_length': 6.006896551724138, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Screening for neurological disease

Given the nature of some neurological diseases to become progressively disabling, early detection and treatment would be very welcome. However, screening for neurological illnesses in the general population has a number of problems. There are only a few neurological conditions that exist in a detectable asymptomatic state prior to development of clinical disease, and a small number of other conditions have early symptomatic stages before the full impact of the disease manifests. In addition, in many neurological conditions, there are no definitive treatments available. There are, of course, many genetic conditions that have neurological manifestations and could be screened, and early access to neurological assessment for some progressive conditions may enable early intervention. Potential target groups include patients with neurogenetic disorders, patients with neurodegenerative disorders, patients with inflammatory disorders, and patients with metabolic disorders.